CliniExperts, one of India's premier Clinical Research Organizations, successfully conducted a phase III study on its ...

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and ...

A new study shows that oral fecal microbiota transplantation (FMT) is a feasible and safe addition to preventing graft-versus-host disease in patients undergoing stem cell transplantation for blood ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Gearing Up to Initiate Phase 3 Ovarian Cancer Trial Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial of ...

Daily low-dose aspirin reduced the risk for colorectal cancer recurrence by roughly half in patients with mutations in the ...

Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a presumptive diagnosis of chronic babesiosis in outpatient ...

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

Advancement of next-generation APJ agonists with discontinuation of azelaprag Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 202 ...

BioAge has also entered a strategic collaboration with Lilly ExploR&D (part of Lilly Catalyze360) to discover two therapeutic antibodies that address novel metabolic aging targets identified by BioAge ...

LOS ANGELES - INmune Bio , Inc. (NASDAQ:INMB), a clinical-stage biotech company valued at $175 million, has announced the treatment of the first patient in the Phase II segment of its ongoing clinical ...